Welcome to the Stanford Division of Hematology, a dynamic center for basic and translational research, clinical trials, patient care, and teaching. Our physicians, scientists, staff, and trainees collaborate to advance the understanding and treatment of hematologic cancers and non-malignant hematologic disorders, all with the goal of improving outcomes for our patients. In pursuit of this objective, we engage with the broader Stanford community to bring innovation and cutting-edge science to our efforts.

There has never been a more exciting time to be a hematologist! The pace of discovery coupled with rapid translation from laboratory to clinic is improving outcomes for patients. Our Division is proud of its strong roots in basic science and we are committed to bringing novel discoveries and therapies to our patients.

Our physicians have expertise in a broad range of hematologic disorders including acute and chronic leukemias, myeloproliferative neoplasms, myelodysplastic syndromes, multiple myeloma, amyloidosis, thrombotic diseases, coagulation disorders, and general hematology.

The basic and translational research efforts of our Division encompass a broad range of focus areas including stem cell biology, cancer and leukemia stem cells, telomere biology, myeloid malignancies, genomics and single-cell multi-omics, the microbiome, human organoids, vascular biology and the role of thrombin-cleaved osteopontin in coagulation and cancer.

Our passionate and dedicated faculty members have mentored and trained leaders in the field of hematology and are excited to inspire and guide the next generation of leading physicians and research scientists.

We are committed to diversity, equity and inclusion within our Division and in academic medicine more broadly.

We invite you to learn more about us through our website.

Rondeep Brar, MD, Named Medical Director for Cancer DSL & SCI’s Assoc. Director for Clinical Care

Dear Colleagues,

We are delighted to announce that Rondeep (Roni) Brar, MD, clinical associate professor of Medicine, has been appointed Stanford Health Care’s Medical Director for the Cancer Destination Service Line (DSL) and Stanford Cancer Institute’s Associate Director for Clinical Care. He began in these dual roles on Monday, February 6.

Over the last decade, Dr. Brar has shown tremendous vision in re-imagining and elevating our health system’s inpatient cancer care services and ambulatory hematology practice. This includes engaging with and leading teams to redesign the Advanced Practice Provider (APP) system, improve inpatient documentation, grow patient volumes, and increase and diversify clinical trial enrollments.

These successes are a testament to Dr. Brar’s strong leadership, expansive expertise, cutting-edge clinical research, and compassionate care. They also reflect his vast institutional knowledge and the strong collegial relationships he has formed across Stanford Medicine. 

After receiving his MD from UCLA in 2007, Dr. Brar completed his internal medicine residency at Stanford in 2010, and his fellowships in hematology and oncology at Stanford in 2012. Dr. Brar was then recruited as a Clinical Assistant Professor in the Department of Medicine, Division of Hematology in 2012. He was subsequently promoted to Clinical Associate Professor in 2018.

Since August 2021, alongside Heather Wakelee, MD, Dr. Brar has served as the Interim Medical Co-Director of the Cancer DSL. During this time, Drs. Brar and Wakelee have re-aligned the structure and leadership of the Cancer Care Programs, reconfigured the leadership cabinet to represent a broader constituent group, and engaged in strategic planning for our joint ventures and future campus expansion.

Dr. Brar will work closely with Drs. Artandi and Seshadri as well as Maria Gonzalez, Executive Director of the Cancer DSL, to shape and implement the future of the Cancer DSL.

Dr. Wakelee will continue to provide interim support through March 2023 as Dr. Brar transitions some of his clinical operations. We want to thank Dr. Wakelee for her dedication and stellar leadership as she continues her exemplary service as the Division Chief of Medical Oncology and Deputy Director of SCI and for her extensive work in enhancing cancer clinical trials.

We also want to express our gratitude to our search committee and the stakeholders across Stanford Medicine who helped facilitate this important search.

We are excited to have Dr. Brar serve in these leadership roles and look forward to his contributions. Please join us in congratulating Dr. Brar on this well-deserved recognition.

Sincerely, 

Steve, Sri, and Niraj